Repository logo
 
No Thumbnail Available
Publication

Pharmacological inhibition of the spliceosome subunit SF3b triggers EJC-independent NMD

Use this identifier to reference this record.
Name:Description:Size:Format: 
Pharmacological_inhibition.pdf14.84 MBAdobe PDF Download

Advisor(s)

Abstract(s)

Spliceostatin A, meayamycin, and pladienolide B are small molecules that target the SF3b subunit of the spliceosomal U2 small nuclear ribonucleoprotein (snRNP). These compounds are attracting much attention as tools to manipulate splicing and for use as potential anti-cancer drugs. We investigated the effects of these inhibitors on mRNA transport and stability in human cells. Upon splicing inhibition, unspliced pre-mRNAs accumulated in the nucleus, particularly within enlarged nuclear speckles. However, a small fraction of the pre-mRNA molecules were exported to the cytoplasm. We identified the export adaptor ALYREF as being associated with intron-containing transcripts and show its requirement for the nucleo-cytoplasmic transport of unspliced pre-mRNA. In contrast, the exon junction complex (EJC) core protein eIF4AIII failed to form a stable complex with intron-containing transcripts. Despite the absence of EJC, unspliced transcripts in the cytoplasm were degraded by nonsense-mediated decay (NMD), suggesting that unspliced transcripts are degraded by an EJC-independent NMD pathway. Collectively, our results indicate that although blocking the function of SF3b elicits a massive accumulation of unspliced pre-mRNAs in the nucleus, intron-containing transcripts can still bind the ALYREF export factor and be transported to the cytoplasm, where they trigger an alternative NMD pathway.

Description

© 2017. Published by The Company of Biologists Ltd.

Keywords

EJC Meayamycin NMD Pladienolide B RNA transport Spliceostatin A Splicing

Pedagogical Context

Citation

J Cell Sci. 2017 May 1;130(9):1519-1531

Research Projects

Organizational Units

Journal Issue

Publisher

The Company of Biologists

CC License

Altmetrics